•
Mar 31

Rockwell Medical Q1 2025 Earnings Report

Rockwell Medical reported a net loss but maintained stable gross profit in Q1 2025 amid a drop in revenue.

Key Takeaways

Despite losing its largest customer, Rockwell Medical kept gross profit steady year-over-year and slightly narrowed its net loss, supported by operational efficiencies and automation initiatives.

Revenue declined 17% YoY to $18.9M due to a major customer transition.

Gross profit remained flat at $3.0M despite the lower revenue base.

Net loss improved to $1.5M from $1.7M in Q1 2024.

Adjusted EPS was -$0.01 and Adjusted EBITDA came in at -$0.4M.

Total Revenue
$18.9M
Previous year: $22.7M
-16.6%
EPS
-$0.01
Previous year: -$0.02
-50.0%
Gross Margin %
16%
Previous year: 14%
+14.3%
Adjusted EBITDA
-$439K
Previous year: -$529K
-17.0%
Adjusted EPS
-$0.01
Previous year: -$0.02
-50.0%
Gross Profit
$3.04M
Previous year: $3.06M
-0.7%
Cash and Equivalents
$17.3M
Previous year: $8.62M
+101.1%
Total Assets
$54M
Previous year: $50.7M
+6.4%

Rockwell Medical

Rockwell Medical

Forward Guidance

Rockwell reaffirmed full-year 2025 guidance despite Q1 revenue decline, expecting margin stability and operational improvements.

Positive Outlook

  • Maintained full-year net sales guidance of $65M–$70M.
  • Confirmed gross margin target range of 16%–18%.
  • Forecast adjusted EBITDA to range between -$0.5M and $0.5M.
  • Increased automation supports expense reduction.
  • New bicarbonate cartridge product expands dialysis portfolio.

Challenges Ahead

  • Q1 revenue down due to major customer transition.
  • Cash decreased by $4.3M from Q4 2024.
  • Continued operating loss in the quarter.
  • Negative free cash flow driven by timing of payments.
  • Seasonal expense pressures weighed on Q1 profitability.